Journals / Turkish journal of nephrology (Online) / 2020 / Cilt: 29 - Sayı: 4

Continuous Erythropoietin Receptor Activator Ameliorates Diabetic Kidney Disease in Rats

Pages
264–272
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum interleukin-1β, tumor necrosis factor-α, and interferon-γ levels were significantly lower; and monocyte chemoaatractant protein 1 levels were significantly higher in group D+CR than those in group D.Conclusion: CERA can protect against DKD, in part, and is related to the suppression of the renal oxidative and inflammatory response.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Diabetic kidney disease (DKD) is still a significant cause of morbidity in patients with diabetes.
📊
Key Findings & Data:In this study, we examined the potential effects of continuous erythropoietin receptor activator (CERA) on oxidative stress, inflammation, and the renin-angiotensin system in a rat model of DKD induced by streptozocin.Materials and Methods: A single intraperitoneal injection of streptozocin (65 mg/kg) was used in male Sprague Dawley rats to induce diabetes.
💡
Conclusion & Impact:Serum interleukin-1β, tumor necrosis factor-α, and interferon-γ levels were significantly lower; and monocyte chemoaatractant protein 1 levels were significantly higher in group D+CR than those in group D.Conclusion: CERA can protect against DKD, in part, and is related to the suppression of the renal oxidative and inflammatory response.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Diabetic kidney disease (DKD) is still a significant cause of morbidity in patients with diabetes. In this study, we examined the potential effects of continuous erythropoietin receptor activator (CERA) on oxidative stress, inflammation, and the renin-angiotensin system in a rat model of DKD induced by streptozocin.Materials and Methods: A single intraperitoneal injection of streptozocin (65 mg/kg) was used in male Sprague Dawley rats to induce diabetes. The rats were randomly divided into 4 groups (n=8/group): diabetic (group D), CERA (group CR), CERA-treated diabetic group (group D+CR), and the control group (group C). The oxidative stress biomarkers, renal function parameters, messenger-ribonucleic acid expression of renin-angiotensin system parameters, and kidney histology were investigated.Results: Creatinine clearance was found to be increased and the urinary albumin-to-creatinine ratio decreased in group D+CR compared with that of group D. Serum malondialdehyde levels were significantly lower, and glutathione and glutathione peroxidase levels were significantly higher in group D+CR than those of group D. Serum interleukin-1β, tumor necrosis factor-α, and interferon-γ levels were significantly lower; and monocyte chemoaatractant protein 1 levels were significantly higher in group D+CR than those in group D.Conclusion: CERA can protect against DKD, in part, and is related to the suppression of the renal oxidative and inflammatory response.

🔖

Cite This Article

GÜNAL, M. Y., EREN, Z., BAKIR, E. A. (2020). Continuous Erythropoietin Receptor Activator Ameliorates Diabetic Kidney Disease in Rats. Turkish journal of nephrology (Online), Cilt: 29 - Sayı: 4, 264–272. https://ajindex.com/articles/374829

References (14)

  1. Mogensen CE. Twelve shifting paradigms in diabetic renal disease and hypertension. Diabetes Res Clin Pract 2008
  2. S2-9. [Crossref] 2. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease challenges, progress, and possibilities. Clin J Am Soc Nephro 2017
  3. [Crossref] 3. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest 2014
  4. [Crossref] 4. Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: A contemporary view. Curr Diabetes Rev 2012
  5. [Crossref] 5. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006
  6. [Crossref] 6. Ishimoto Y, Tanaka T, Yoshida Y, Inagi R. Physiological and pathophysiological role of reactive oxygen species and reactive nitrogen species in the kidney. Clin Exp Pharmacol P 2018
  7. [Crossref] 7. Navarro-Gonzalez JF, Mora-Fernandez C, de Fuentes MM, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011
  8. [Crossref] 8. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, et al. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol P 2010
  9. [Crossref] 9. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, et al. Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press R 2008
  10. [Crossref] 10. Topf JM. CERA: Third-generation erythropoiesis-stimulating agent. Expert Opin Pharmaco 2008
  11. [Crossref] 11. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007
  12. [Crossref] 12. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of sirt1 in diabetic wistar fatty (fa/fa) rats: A model of type 2 diabetes. Exp Diabetes Res 2011
  13. 908185. [Crossref] 13. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979
  14. [Crossref] 14. Beutler E, Duron O, Kelly BM. Improved method for